Eli Lilly’s New Diabetes and Weight-loss Drug, Mounjaro, Launches in India
Eli Lilly and Company, an international pharmaceutical corporation, announced on Thursday that its blockbuster diabetes and weight-loss drug, Mounjaro, has been approved by India’s drug regulator, the Central Drugs Standard Control Organization (CDSCO). This approval allows the company to launch the drug in the Indian market.
Background of Mounjaro
Mounjaro, also known as tirzepatide, is a once-weekly GLP-1 receptor agonist and a once-weekly GIP receptor agonist. It is designed to help manage type 2 diabetes and obesity by mimicking the functions of natural hormones in the body. The drug has already been approved in the United States, Europe, and other countries.
Impact on Individuals
For individuals in India diagnosed with type 2 diabetes and obesity, the availability of Mounjaro is a significant development. According to the International Diabetes Federation, India has the second-highest number of people living with diabetes in the world. The country also has a high prevalence of obesity, particularly in urban areas. Mounjaro’s approval in India provides a new treatment option for managing these conditions.
The drug is administered through subcutaneous injections once a week. It helps regulate blood sugar levels and reduces appetite, leading to weight loss. Clinical trials have shown that Mounjaro can lower HbA1c levels, a key measure of long-term blood sugar control, by up to 2.1% compared to placebo. It can also lead to significant weight loss, with an average weight reduction of 12.4 pounds (5.6 kilograms) in clinical trials.
Impact on the World
The launch of Mounjaro in India is not just significant for the Indian market but also for the global diabetes and obesity community. With India being the second-most populous country in the world, the availability of this drug in the country can lead to a substantial impact on the global diabetes and obesity burden.
Furthermore, the approval of Mounjaro in India may pave the way for its approval in other countries, including those in the Asia-Pacific region. The drug’s success in the Indian market could potentially influence regulatory agencies in other countries to expedite their review processes.
Conclusion
Eli Lilly’s Mounjaro, a once-weekly GLP-1 receptor agonist and GIP receptor agonist, has been approved for use in India, providing a new treatment option for individuals managing type 2 diabetes and obesity. With a significant number of people in India living with these conditions, the availability of Mounjaro can lead to a substantial impact on the country’s healthcare landscape. Furthermore, the approval of Mounjaro in India may influence regulatory agencies in other countries to expedite their review processes, potentially leading to wider availability of the drug globally.
- Eli Lilly’s Mounjaro, a once-weekly GLP-1 receptor agonist and GIP receptor agonist, has been approved for use in India.
- The drug is designed to help manage type 2 diabetes and obesity by mimicking the functions of natural hormones in the body.
- India has the second-highest number of people living with diabetes in the world, making the approval of Mounjaro particularly significant.
- The drug has already been approved in the United States, Europe, and other countries.
- Mounjaro can lower HbA1c levels by up to 2.1% compared to placebo and lead to significant weight loss.
- The approval of Mounjaro in India may pave the way for its approval in other countries, particularly in the Asia-Pacific region.
